“…Of pertinence to immunotherapy studies, synergism between host antitumor immunity, surgery, and combination chemotherapy has been demonstrated in the CDsF 1 tumor system [12,13,23]. Further, in this CD8F 1 animal model, the immunostimulant, zymosan, produces an augmentation of tumor cures when employed as an adjuvant to combination chemotherapy following surgical removal of the CD8F 1 murine breast cancer 114, 15].…”